Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
March 15, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, March 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
January 21, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, UK, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’)...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
September 08, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8,
2014 - Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Awarded $200,000 Research Grant from PPMD
June 27, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, June 27, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy
June 25, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, June 25, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Holding N.V. to Webcast Conference Call Discussing 1st Quarter 2014 Financial Results and Corporate Update on May 20, 2014
May 13, 2014 08:57 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, May 13, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that the
Company will host a conference call and live audio webcast on
Tuesday, May 20,...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Present at the 66th Annual American Academy of Neurology (AAN) Annual Meeting and the 39th Annual Deutsche Bank Health Care Conference
April 28, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, April 28, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical
company focusing on rare diseases with a high unmet medical need,
today...
![CureDuchenne logo](/news-release/logo/220973/0/220973.jpg?lastModified=12%2F10%2F2016%2018%3A09%3A32&size=2)
CureDuchenne Announces Third Annual Scientific Summit and Worlwide Webcast
January 24, 2012 13:51 ET
|
CureDuchenne
NEWPORT BEACH, Calif., Jan. 24, 2012 (GLOBE NEWSWIRE) -- CureDuchenne, a national nonprofit that funds research to find a cure for Duchenne muscular dystrophy, a lethal muscle disease that affects...